Red Light Holland - Advisor, Akwasi Owusu Bempah.
Advisor, Akwasi Owusu Bempah.
Source: Toronto International Festival of Authors.
  • Red Light Holland (TRIP) has hired drug law expert Akwasi Owusu-Bempah as its newest advisor
  • Owusu-Bempah is a respected Canadian academic and leader in drug law reform
  • The appointment aims to enhance the company’s social advocacy and regulatory relationships
  • Red Light Holland is focused on the production, growth and sale of magic truffles in the Netherlands
  • Red Light Holland (TRIP) is unchanged trading at $0.09 per share

Red Light Holland (TRIP) has hired drug law expert Akwasi Owusu-Bempah as its newest advisor.

Owusu-Bempah is a respected Canadian academic and leader in drug law reform with extensive experience across public and private sectors in Canada and internationally. His academic work examines inequality in drug law enforcement across North America.

He has collaborated with major media outlets and lobbied federal governments on drug policy, as well as collaborated with some of the world’s largest cannabis companies on corporate responsibility.

Owusu-Bempah also recently sat on Health Canada’s Expert Task Force on Substance Use.

“Akwasi is another wonderful asset to the Red Light team and we are grateful as we are confident his experience, knowledge and past lobbying efforts, plus his educational pieces, will help open the eyes and ears of health regulatory bodies across the world,” stated Todd Shapiro, Red Light Holland’s CEO.

“I am excited to work with Red Light Holland and its efforts to bring psilocybin from underground to mainstream,” added Owusu-Bempah. “Todd and his team have shown great leadership in the psychedelics space and I look forward to contributing to the company’s social purpose and advocacy strategy.”

Red Light Holland is focused on the production, growth and sale of magic truffles in the Netherlands.

Red Light Holland (TRIP) is unchanged trading at $0.09 per share as of 10:11 am EST.

More From The Market Online

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.